Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
27.50
-0.17 (-0.60%)
Streaming Delayed Price
Updated: 12:25 PM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,288,523
Open
27.50
Bid (Size)
27.50 (400)
Ask (Size)
27.51 (500)
Prev. Close
27.67
Today's Range
27.01 - 27.94
52wk Range
8.730 - 27.72
Shares Outstanding
692,072,184
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The market is filled with gapping stocks in Friday's session.
↗
February 06, 2026
Via
Chartmill
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
Performance
YTD
+25.4%
+25.4%
1 Month
+24.1%
+24.1%
3 Month
+29.9%
+29.9%
6 Month
+146.2%
+146.2%
1 Year
+154.9%
+154.9%
More News
Read More
Get insights into the top gainers and losers of Friday's pre-market session.
↗
February 06, 2026
Via
Chartmill
Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?
↗
February 06, 2026
Via
Stocktwits
Earnings Scheduled For November 10, 2025
↗
November 10, 2025
Via
Benzinga
Earnings Preview For Roivant Sciences
↗
November 07, 2025
Via
Benzinga
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
February 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
February 06, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
February 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
January 26, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
↗
December 11, 2025
Via
Benzinga
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
December 11, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant (ROIV) Q2 2026 Earnings Call Transcript
↗
November 27, 2025
Via
The Motley Fool
Topics
Earnings
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
Looking Into Roivant Sciences Ltd's Recent Short Interest
↗
November 11, 2025
Via
Benzinga
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
November 10, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
October 27, 2025
From
Roivant Sciences
Via
GlobeNewswire
6 Analysts Assess Roivant Sciences: What You Need To Know
↗
September 18, 2025
Via
Benzinga
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
↗
September 17, 2025
Via
Stocktwits
Why Roivant Sciences Stock Is Soaring Today
↗
September 17, 2025
Via
The Motley Fool
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
↗
September 17, 2025
Via
Benzinga
Wednesday's session: gap up and gap down stocks
↗
September 17, 2025
Via
Chartmill
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
↗
September 17, 2025
Via
Benzinga
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease
↗
September 17, 2025
Via
Investor's Business Daily
Frequently Asked Questions
Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 27.50
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 02/10/26 12:25 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 19.04B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 19B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
